800
Views
6
CrossRef citations to date
0
Altmetric
Hematological Malignancy

Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure

, , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Andrés Gomez-de-León, David Gómez-Almaguer, Guillermo J. Ruiz-Delgado & Guillermo J. Ruiz-Arguelles. (2017) Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Review of Hematology 10:9, pages 809-819.
Read now

Articles from other publishers (5)

Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman & Joanna Zawitkowska. (2021) The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?. International Journal of Molecular Sciences 22:21, pages 12089.
Crossref
Nikola Geskovski, Nadica Matevska-Geshkovska, Simona Dimchevska Sazdovska, Marija Glavas Dodov, Kristina Mladenovska & Katerina Goracinova. (2021) The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors. Beilstein Journal of Nanotechnology 12, pages 375-401.
Crossref
Joseph J. Caumanns, Anne van Wijngaarden, Arjan Kol, Gert J. Meersma, Mathilde Jalving, René Bernards, Ate G.J. van der Zee, G. Bea A. Wisman & Steven de Jong. (2019) Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. Cancer Letters 461, pages 102-111.
Crossref
Barbara Cortese, Stefania D’Amone & Ilaria Palamà. (2018) Wool-Like Hollow Polymeric Nanoparticles for CML Chemo-Combinatorial Therapy. Pharmaceutics 10:2, pages 52.
Crossref
Hongbin Wang, Haitian Quan & Liguang Lou. (2017) AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. Biochemical and Biophysical Research Communications 489:1, pages 14-20.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.